Low confidence — this score is based on limited public data (mostly aggregate ratings, with little independent discussion or review detail), so it may not reflect real-world quality.
What it is
Overview
An FDA-cleared AI system that analyzes tissue samples and pathology slides for drug development and clinical diagnostics. Built as a proprietary computational pathology model trained on medical imaging data. The vendor claims 90% of top biopharma companies use the system for research applications. Primary users are pathologists, clinical researchers, and drug development teams at pharmaceutical companies.
At a glance
Usability & Quality overview
Best for
- Biopharma R&D for biomarker discovery in drug development
- Labs needing vendor-agnostic whole-slide image integration (DICOM from Leica/Philips/Hamamatsu)
Watch out for
- Zero peer-reviewed clinical validation as of May 2026
- 'Underwhelming' model effectiveness in US clinical settings
- High maintenance costs relative to performance
Real product, not a wrapperIndependent product
PathAI offers specialized AI trained specifically for pathology analysis with proprietary medical imaging data and FDA regulatory clearance. This represents genuine domain expertise beyond what general AI models like ChatGPT can provide for medical diagnostics.
Strong evidenceQuality score
PathAI AI-powered pathology platform for drug development with strong vendor-agnostic slide integration, but subpar clinical effectiveness in US workflows and no peer-reviewed validation
This score is our editorial judgment, computed automatically from the sources, weights, and dates shown above. It reflects the data we could verify as of July 9, 2026, not a guarantee or statement of fact about PathAI. Third-party ratings and quotes belong to their original platforms and authors. Thin data lowers our confidence label, and we say so instead of guessing. Work on PathAI? Dispute any datapoint and we will review it, publish your response, and correct verified errors.
PricingUnknown
Individual plan details haven't been verified yet — they'll appear here on the next data refresh.
Capabilities
Key features
Healthcare & Medical Assistant
Supports clinical documentation, triage, and health questions with AI assistance
Image Recognition
Identifies objects, scenes, and content within images and returns labels
The honest take
What users love & flag
Distinct themes surfaced across user reviews — each grounded in real review text, ranked by how often it comes up.
Questions
Frequently asked
What is PathAI?
PathAI is an AI-powered pathology platform that transforms pathology workflows for biopharma companies and anatomic pathology laboratories. Its core solution, AISight, is a cloud-native digital pathology platform that provides AI-assisted analysis of digital pathology images for diagnostics and drug development. The platform has FDA clearance and is used by 90% of the top 15 biopharma companies.
Is PathAI FDA-approved for medical use?
Yes, PathAI's AISight Dx platform has received FDA clearance for primary diagnosis, making it the first AI-powered pathology tool to receive FDA qualification for MASH clinical trials. This FDA clearance allows the platform to be used for actual medical diagnosis, not just research purposes.
What specific AI tools does PathAI offer for clinical trials?
PathAI offers several specialized AI tools including AIM-MASH AI Assist specifically for clinical trials, and AIM-HI UC and IBDExplore for standardized histopathology endpoints. These tools are designed to support drug development by providing consistent, AI-powered analysis of pathology samples in pharmaceutical research.
How does PathAI train its AI algorithms?
PathAI leverages a proprietary network of over 450 board-certified pathologists who have contributed more than 32.5 million annotations to train and validate the AI algorithms. This extensive dataset of expert annotations helps ensure the AI models are accurate and reliable for pathology analysis.
What types of organizations use PathAI?
PathAI serves both biopharma companies and anatomic pathology institutions, including academic medical centers, reference laboratories, and health systems. The platform is used by 90% of the top 15 biopharma companies and has major partnerships with organizations like Labcorp for nationwide deployment and MedStar Health for advanced AI applications.
Can PathAI integrate with existing laboratory workflows?
Yes, PathAI's cloud-native architecture and open design enable integration with existing laboratory workflows. The platform provides enterprise-grade workflow solutions specifically designed for digital pathology applications, allowing labs to incorporate AI analysis without completely overhauling their current systems.
What makes PathAI different from traditional pathology analysis?
Traditional pathology relies on manual microscopy and subjective interpretation by pathologists, which creates bottlenecks in clinical trials and diagnostic processes. PathAI automates and standardizes this analysis using AI, providing faster, more consistent results while serving as a centralized hub for case management and image management.
Is PathAI being acquired by another company?
Yes, PathAI has entered into a definitive merger agreement to be acquired by Roche. This acquisition by the major pharmaceutical and diagnostics company suggests strong industry validation of PathAI's technology and market position.
Compare PathAI
Compare with another toolMore Like This
